Down 86% This Year, Is Ginkgo Bioworks Stock a Bargain Now?
To say the past year has been rough for investors in Ginkgo Bioworks (NYSE: DNA) would be an understatement of the highest order. As of Aug 14, shares of the synthetic-biology stock were down by 86% in 2024.
A beaten-down price isn't the only way the stock market has signaled low expectations. Ginkgo stock has been trading at a steeply negative enterprise value.
It's a debt-free company that finished June with $730 million in cash and cash equivalents. The stock has been beaten down so severely, though, that you could buy every outstanding share for just $524 million at recent prices.
Source Fool.com
